Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
